Back to results
US 2026/0217797 A1Published application
Coronavirus antibodies and therapeutic uses thereof
AssigneeTakeda Pharmaceutical Company Limited
InventorsJerry Thomas, Weihong Yu, Dianna Lundberg, David Bouck, Stefan Koester, Kurt Y. Eng, James Geoghegan, C. Garrett Rappazzo, Caitlin Stein, Rebekah Costello, Shelley Izquierdo, William D. Harriman
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antibodies that bind to coronavirus spike protein (e.g., SARS-CoV-2 spike protein), and methods of use thereof (e.g., treatment of subjects infected with SARSCoV-2).
Claims106
An antibody that binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, wherein the antibody comprises:
- a heavy chain variable domain (VH) comprising a heavy chain complementary determining region 1 (CDR-H1) comprising the amino acid sequence of FTFX1NFAMH (SEQ ID NO:
- 230), wherein X1 is S, T, D or E;
- a heavy chain complementary determining region 2 (CDR-H2) comprising the amino acid sequence of VIX2YDGINX3YYADSVKG (SEQ ID NO:
- 231), wherein X2 is A, L, I, V, E, or D, and X3 is K, R, D or E;
- a heavy chain complementary determining region 3 (CDR-H3) comprising the amino acid sequence of ARAQNYYDRX4GTLQLDAFDI (SEQ ID NO:
- 232), wherein X4 is S, T, Y, H;
- and/or
- a light chain variable domain (VL) comprising a light chain complementary determining region 1 (CDR-L1) comprising the amino acid sequence of X5ASX6GIRNDLG (SEQ ID NO:
- 233), wherein X5 is R, K, V, L, A, or I and X6 is Q, N, E or D;
- a light chain complementary determining region 1 (CDR-L2) comprising the amino acid sequence of X7ASSLX8S (SEQ ID NO:
- 234), wherein X7 is A, V, L, I, E or D, and X8 is Q, N, D or E;
- and a light chain complementary determining region 1 (CDR-L3) comprising the amino acid sequence of LQX9YNYPLT (SEQ ID NO:
- 235), wherein X9 is N, Q, E or D.
10 more elements
An antibody that binds to a SARS-CoV-2 spike protein, wherein the antibody comprises:
- a VH comprising a CDR-H1 comprising the amino acid sequence of FTFX1RYWMH (SEQ ID NO:
- 242), wherein X1 is S, T, K or R;
- a CDR-H2 comprising the amino acid sequence of RINSDGSSTTYADSVX2G (SEQ ID NO:
- 243), wherein X2 is K, R, D or E;
- a CDR-H3 comprising the amino acid sequence of ARELYYYDX3RGX4EEGEGWFDP (SEQ ID NO:
- 244), wherein X3 is S, T, K and R, and X4 is A, V, I, L, W or F;
- and/or
- a VL comprising a CDR-L1 comprising the amino acid sequence of TGISSNIGAX5YDVH, wherein X5 is G, N, Q, D, or E (SEQ ID NO:
- 245);
- a CDR-L2 comprising the amino acid sequence of GNSNRPX6 (SEQ ID NO:
- 246), wherein X6 is S, T, K or R;
- and a CDR-L3 comprising the amino acid sequence of QX7SDRX8X9SGSV (SEQ ID NO:
- 247), wherein X7 is S, T, A, I, L or V, and X8 is S, T, or Y, and X9 is L, I, or V.
10 more elements
An antibody that binds to a SARS-CoV-2 spike protein, wherein the antibody comprises:
- a VH comprising a CDR-H1 comprising the amino acid sequence of X1TFSSX2DMS (SEQ ID NO:
- 254), wherein X1 is F, W or P, and X2 is Y, T or S;
- a CDR-H2 comprising the amino acid sequence of GISGX3GAITYYTDSVKG (SEQ ID NO:
- 255), wherein X3 is S, T, D or E;
- a CDR-H3 comprising the amino acid sequence of TKENNRX4TFFDY (SEQ ID NO:
- 256), wherein X4 is N, Q, A, L, I, V, or G;
- and/or
- a VL comprising a CDR-LT comprising the amino acid sequence of X5ASQTVRSDLA (SEQ ID NO:
- 257), wherein X5 is R, K, S or T;
- a CDR-L2 comprising the amino acid sequence of GX6STRAT (SEQ ID NO:
- 258), wherein X6 is A, V, L, I or G;
- and a CDR-L3 comprising the amino acid sequence of QQYYEWPPHSDS (SEQ ID NO:
- 186).
10 more elements
An antibody that binds to a SARS-CoV-2 spike protein, wherein the antibody comprises:
- a VH comprising a CDR-H1 comprising the amino acid sequence of FTX1DDYAMH (SEQ ID NO:
- 264), wherein X1 is F, W, I, or L;
- a CDR-H2 comprising the amino acid sequence of GX2SWNX3GTIGYADSVKG (SEQ ID NO:
- 265), wherein X2 is I, L, V, A, S or T, and X3 is S, T or G;
- comprising CDR-H3 comprising the amino acid sequence of X4KDRKREDPSLGGMDV (SEQ ID NO:
- 266), wherein X4 is G T, L, A or V;
- and/or
- a VL comprising a CDR-L1 comprising the amino acid sequence of X5GNNIGSKSVH (SEQ ID NO:
- 267), wherein X5 is G, L, I, A or V;
- a CDR-L2 comprising the amino acid sequence of DDTDRPS (SEQ ID NO:
- 123);
- and a CDR-L3 comprising the amino acid sequence of QVWDX6X7SDX8YV (SEQ ID NO:
- 268), wherein X6 is S, T, I, L, A or V, and X7 is S, T, D or E, and X8 is H, S, T, E or D.
10 more elements
An antibody that binds to a SARS-CoV-2 spike protein, wherein the antibody comprises:
- a VH comprising a CDR-H1 comprising the amino acid sequence of FTFADYX1MS (SEQ ID NO:
- 274), wherein X1 is A, V, S or T;
- a CDR-H2 comprising the amino acid sequence of FIRSX2PYGGTTEYAASVKG (SEQ ID NO:
- 275), wherein X2 is K, R, E, and D;
- a CDR-H3 comprising the amino acid sequence of SRDPWYCSGGDCYAVTGSWFDP (SEQ ID NO:
- 67);
- and/or
- a VL comprising a CDR-L1 comprising the amino acid sequence of QASX3DIKX4YLN (SEQ ID NO:
- 276), wherein X3 is Q, N, K or R and X4 is K, R, N, or Q;
- a CDR-L2 comprising the amino acid sequence of DX5SNLET (SEQ ID NO:
- 277), wherein X5 is V, I, L, A, N or Q;
- and a CDR-L3 comprising the amino acid sequence of QQYX6X7LPQT (SEQ ID NO:
- 278), wherein X6 is D, E, F or W, and X7 is N or Q.
10 more elements
An antibody that binds to a SARS-CoV-2 spike protein, the antibody comprising:
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 1, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 2, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 3;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 9, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 10, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 11;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 12, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 13, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 14;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 17, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 18, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 19;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 20, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 21, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 22;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 25, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 26, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 27;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 28, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 29, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 30;
- a VH comprising a CDR-H1 comprises the amino acid sequence of SEQ ID NO:
- 33, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 34, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 35;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 36, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 37, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 38;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 49, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 50, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 51;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 52, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 53 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 54;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 57, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 58, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 59;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 60, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 61, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 62;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 73, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 74, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 75;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 76, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 77, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 78;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 81, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 82, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 83;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 84, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 37, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 85;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 88, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 89, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 90;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 91, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 92, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 93;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 96, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 97, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 98;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 99, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 100, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 101;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 104, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 105, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 106;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 107, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 108, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 109;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 112, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 113, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 114;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 115, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 45, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 116;
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 127, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 128, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 129;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 4, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 5, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 130;
- or
- a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 141, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 142, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 143;
- and/or a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 144, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 145, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 146.
118 more elements
Dependencies are inferred from the claim text.